Last Friday, the FDA’s Anti-Infective Drugs Advisory Committee recommended the approval of Actavis’ New Drug Application (NDA) for ceftazidime-avibactam for the treatment of hospitalized patients.
Last Friday, the FDA’s Anti-Infective Drugs Advisory Committee recommended the approval of Actavis’ New Drug Application (NDA) for ceftazidime-avibactam for the treatment of hospitalized patients (when limited or no treatment options are available) for complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract infections (cUTI) (including acute pyelonephritis) caused by gram-negative pathogens. The committee found the scientific and clinical evidence submitted by Cerexa (a wholly-owned subsidiary of Actavis) adequately demonstrated the safety and efficacy of ceftazidime-avibactam in the treatment of cIAI and cUTI.
Despite the support for approval in the above indications, the committee voted against the approval of the combination for hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP) and bacteremia.
Additionally, the panel raised concerns around labeling, particularly for patients with renal impairment.
Actavis intends to work closely with the FDA regarding the data required that would facilitate approval, and expects a response from the FDA regarding approval status in the first quarter of 2015.
David Nicholson, senior vice president, Global Brands R&D, Actavis stated, “We are pleased with the committee’s positive recommendation for ceftazidime-avibactam. It reinforces our belief in the safety and efficacy of the compound and its potential to address significant unmet needs as a new treatment option for patients with serious and life-threatening infections.”
The FDA is not obligated to follow the advice of its panels, but normally does so.
ISS has over a decade of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComs per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact email@example.com.
Do you have an upcoming Advisory Committee Meeting?
Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more
FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more
One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more
US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us